By Marcus Julius Zanon, 9 October, 2026.
A vaccine patch looks simple: a small surface applied to the skin. The patent documents behind it reveal a more demanding engineering problem. Where should the vaccine be placed? How can its activity be preserved? How much material reaches each patch? What makes application consistent?
For Brazilian institutions considering new vaccine technologies, these questions provide a useful starting point for technology-transfer assessment. They connect the visible product to the production capabilities needed to reproduce it.
WHO identifies microarray patches as a promising delivery technology, with potential advantages in administration and thermostability. Those possibilities should be evaluated for each product and formulation. They are not automatic properties of every patch. [1]
A review of two PatBase exports illustrates how different inventions address different parts of this challenge. The documents provide technical disclosures and research leads; they do not, by themselves, establish clinical effectiveness, commercial readiness or permission to manufacture.
The Corium family identified as 43145231 describes polymeric microprojection arrays containing a vaccine, including designs in which the vaccine is placed in one layer. This makes the position of the active material part of the invention.
Two documents associated with Liaoning Chengda offer a particularly useful comparison involving rabies vaccines. CN110193082 A describes producing a microneedle structure, treating and sterilizing it, and subsequently applying a vaccine-containing coating. CN110193137 A describes a dissolving patch manufactured through moulding, drying and assembly of the needle body and backing. [2]
These are different production routes for a related delivery objective. Their industrial requirements cannot be assumed to be interchangeable. Evaluating a transfer would require examining how the biological material encounters each process step, how loading is controlled and how the finished product is tested.
The first document’s sequence also raises a practical question: how is the final product’s microbiological quality maintained after the vaccine coating is applied? An abstract that describes sterilizing a substrate does not, on its own, answer every question about the finished combination.
University College Cork’s US20210252132A1 describes compositions and methods for stabilizing vaccines in solid dosage formats. Its disclosed ingredients include an antioxidant, sugars, salts and, in some embodiments, a water-soluble polymer. Microneedle patches are among the contemplated formats. [3]
This illustrates why reproducing the physical shape of a patch may be insufficient to reproduce its intended performance. Formulation and drying conditions are part of the technical package to investigate.
The exports also contain an instructive qualification. The abstract for Pittsburgh’s family 87457933, represented by US2023145599 AA in PatBase, reports adenovirus infectivity retained for at least one month at 4°C. That is a specific storage statement involving refrigeration, not evidence that every vaccine patch can be distributed at ambient temperature. [2]
For any proposed product, the relevant questions include the tested formulation, temperature, duration, packaging, assay and acceptance criteria. A broad statement that a technology is “stable” leaves too much unresolved.
Vaxxas’s US20200182605A1 addresses detecting the amount of coating on a substrate, including vaccine material on a microarray patch. This is an important example because the invention concerns measurement rather than simply the shape of the delivery device. [4]
A technology-transfer assessment should therefore examine the associated analytical methods. How will the receiving institution measure coating consistency? What reference materials and calibration procedures are needed? How will a failed result be investigated?
Coating quantity, retained biological activity and the dose actually delivered are separate questions. Evidence about one should not silently substitute for evidence about the others.
Another Vaxxas family, 73172696, describes differential coating of microprojections, including approaches involving potentially incompatible components of multivalent vaccines. Kindeva-associated family 63050052 describes aluminium-adjuvanted coating formulations incorporating sugars or sugar alcohols and a thickener. Together, these disclosures show that depositing a vaccine on a small structure is itself a field of formulation and process development. [2]
Even a consistently manufactured patch must be applied appropriately. Vaxxas family 73130229 describes an actuator intended to reduce trigger force while preserving the mechanical action used to apply microprojection arrays.
Queen’s University Belfast family 106121758 describes a moisture-responsive colour change in the patch baseplate, intended to align with substance delivery or capture. This provides an engaging example of user feedback built into device design. It should not be interpreted, without supporting validation, as proof that a complete vaccine dose has been delivered. [2]
For a receiving institution, the implication is practical: the patch, any applicator, operating instructions and performance tests should be evaluated together.
The second export lists Brazilian publications associated with several relevant platforms. Examples include BR112012028263 B1, concerning microneedle applicators; BR112015022432 B1, concerning microstructure arrays for active-agent delivery; and BR112022021344 A2, concerning coronavirus-vaccine-coated microprotrusions. [2]
These records justify a Brazilian investigation. They do not establish current enforceability, infringement or freedom to operate. Those conclusions require examination of the relevant Brazilian claims, prosecution history and current official status against a defined product and process.
The broader point is that the assessment should identify which components of a proposed manufacturing route require further investigation. A family number or an international publication is a starting point, not a substitute for that work.
Taken together, these examples suggest a practical framework for evaluating a proposed transfer:
| Capability | Evidence to request |
|---|---|
| Reproduce the formulation | Composition, material specifications, preparation procedures and stability evidence |
| Manufacture the patch | Equipment requirements, process parameters, controls and representative batch records |
| Measure product quality | Analytical methods, reference materials, acceptance criteria and method-transfer evidence |
| Apply the product consistently | Applicator specifications, operating instructions and application-performance evidence |
| Maintain performance during storage | Packaging specifications and product-specific stability data |
| Understand the intellectual-property position | Relevant claims, territorial coverage, ownership/licensing evidence and current status verification |
These are proposed assessment questions, not findings that any named institution has already satisfied them.
For universities and technology-transfer offices, patent intelligence can help organize the discussion with researchers and potential partners. The documents identify technical problems, possible solutions and subjects requiring further evidence. Their value increases when those disclosures are connected to the receiving institution’s actual capabilities.
The central question for a Brazilian technology-transfer project is therefore concrete: after implementation, can the receiving team make the product consistently, explain its performance, investigate deviations and sustain production?
Vaccine-patch patents offer a useful way to ask that question before committing to a manufacturing pathway.
This exploratory article draws on two user-supplied PatBase exports: patbase_export_47305311.docx and patbase_export_47305311-now2.docx. Each contains 500 distinct family IDs; 411 overlap, producing 589 distinct IDs across both exports. These are dataset counts, not a verified comprehensive landscape. Fifty-five families in the second export list at least one Brazilian publication, including broader technologies outside the article’s narrow scope.
The article uses selected abstracts and bibliographic/member records, supplemented by public patent documents for the stabilization and coating-quality examples. It does not report an exhaustive claims analysis, independently validated clinical performance, a complete market ranking or a freedom-to-operate opinion. Search history and export completeness were not established. Names reflect the supplied records and are not an independent audit of present ownership.